CA-VERIMATRIX
24.2.2020 17:42:14 CET | Business Wire | Press release
Regulatory News:
Verimatrix , (Paris:VMX) (Euronext Paris: VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video content, endpoint devices, software and applications, today announced that Albania’s largest IPTV and OTT service provider TiBO has deployed Verimatrix Multi-DRM via the Verimatrix Secure Cloud to protect premium content that extends beyond traditional television.
Using a cloud-based Software-as-a-Service (SaaS) model, the Verimatrix Multi-DRM solution offers TiBO a convenient and cost-effective alternative to on-premise systems and operations. It is further supported by a vast range of pre-integrations with leading ecosystem partners, including Magoware, which was another key motivator for TiBO’s deployment.
“Because video content offered in Albanian language is highly sought after by pirates, it is more challenging to receive approval from studios to distribute their content in the region without a strong reputation for keeping content protected,” said Adnand Mahmuti, CEO at TiBO. “Verimatrix is able to offer us the complete package – the DRM capabilities we need, delivered via a simple and secure cloud infrastructure, underscored by its proven ability to maximize revenue for video service providers in Albania and across the world.”
Facing a high volume of illegal distribution in the region, TiBO originally enlisted Verimatrix to optimize revenue security for its OTT service, but by choosing a cloud-based security infrastructure, it was also able to unlock several added benefits. Deploying Verimatrix Multi-DRM via Verimatrix’s cloud-based infrastructure has enabled TiBO to reduce the complexity of its operations, while the SaaS business model minimizes CAPEX. Costs and complexities are further reduced by a simple HLS-only streaming format which allows content to be encoded and encrypted just once.
“This cloud-based Verimatrix Multi-DRM deployment truly checks all of the boxes for TiBO with simplicity at the core,” said Verimatrix Chief Operating Officer Asaf Ashkenazi. “Because the security framework will adapt to studio-required changes in security regime, TiBO – and the studios issuing premium content – can rest assured they will always be a step ahead of pirates.”
Verimatrix Multi-DRM offers a comprehensive, multi-screen and multi-DRM solution for premium content security and monetization with several value-add options. The deployment has laid the groundwork for TiBO to extend OTT distribution to SmartTVs, as well as tap into watermarking and analytic capabilities.
To learn more about Verimatrix Multi-DRM and how it offers a compelling choice in the busy OTT market, please visit www.verimatrix.com/solutions/multi-drm .
About TiBO
TiBO is the largest Albanian IPTV/OTT platform distributing prime video content for Albanian audiences worldwide. TiBO collaborates with the largest Content providers to offer Albanian TV shows, Movies, News, and live sport. Starting with investing simply in better connectivity TiBO has leveled up the audience's demand. The innovation brought by the OTT content solution to Albanian citizens simultaneously freed ex-pats from geographic restrictions and broadcast schedules, and fundamentally transformed the way video is consumed.
With Global ecosystem leaders on the side, TiBO continuously invests in new technologies that improve and secure content distribution. TiBO is highly engaged to protect the content by delivering qualitative and secured entertainment in all playout devices for big and small screens (STB-s, Smart TV-s; Mobiles and tablets). For the end-user, it’s all fairly seamless and indistinguishable but beneath the technology, there is a range of business models that inevitably bring to another level not only the television experience but the entire industry. What TiBO has ignited already is an irreversible shift to content distribution via OTT which pushes further than ever the boundaries, to enable new types of applications and services across the industry.
To find out more about TiBO IPTV/OTT distribution Platform visit www.tibo.tv or follow in social media, Twitter , Facebook , LinkedIn , Instagram .
About Verimatrix
Verimatrix (Euronext Paris: VMX), formerly known as Inside Secure, is a trusted business partner providing software security and business intelligence solutions that protect content, applications, and devices across multiple markets. Many of the world’s largest service providers and leading innovators trust Verimatrix to protect systems that people depend on every day. With more than 20 years of experience and the top minds in the industry, the company is uniquely positioned to understand and proactively anticipate security and business challenges for customers. Verimatrix partners provide innovative, customer-friendly solutions that are cost-effective, easy to deploy and supported with responsive customer service teams based worldwide. To learn more, visit www.verimatrix.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200224005579/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
